NICE recommended semaglutide 2.4 mg (TA875, 2023) for use within specialist Tier 3 weight management services in adults with a BMI of 35 kg/m (or 32.5 kg/m in people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background) with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in specific circumstances
WERE READY WHEN YOU ARE
Semaglutide is generally well-tolerated, but like all medications, it can have risks and side effects
Patients seeking meaningful fat loss outcomes should pursue GLP-1 therapy through a licensed prescriber, not rely on over-the-counter antioxidants that address a completely different physiological problem
Food and Drug Administration (FDA) Consumer Updates on GLP-1 Receptor Agonist Efficacy, Approved Semaglutide High-Dose Guidance, and Public Safety Alerts (USA Gov)